I've lost 4st on Mounjaro without any grim side effects – it's all thanks to two hacks that put a stop to them
A WOMAN has revealed that she has lost over 4st using weight loss injections.
Kathryn Elizabeth, from the UK, took to social media to share her journey and the tips she had for others on Mounjaro.
2
2
After being on Mounjaro for six months, she shared the things she wish she knew before starting her journey.
In the clip, she said: "The weight won't magically come off, you need to have a lifestyle change."
She said walking and a calorie deficit were vital to shift weight even with the help of the fat loss jab.
Kathryn also warned that you won't notice the weight loss on yourself for months even if it is happening.
"That being said, my face was the first place I noticed it," she explained.
Kathryn also had some advice for those dealing with negative side effects of the drug.
She said: "Drink at least 3 litres of water a day, trust me. It makes the world of difference for how you feel day to day and helps numerous side effects."
After losing 4st, she also revealed fibre was super important to help shift the weight.
With weight loss jabs, many people feel less hungry so struggle to eat enough fibre.
But Kathryn recommended fibre supplements to make sure you get the daily recommendation.
I lost 98lb on Mounjaro but it's surprise side benefit that is life-changing
"I'm a terrible veg eater so I get mine mainly through vitamins, oats or fibre bars you can buy at the shops. Graze do one that is sticky toffee pudding flavour and it's great," she added.
Kathryn also warned those going on the drug not to totally restrict what they eat and drink.
She said you can have everything in moderation instead of changing your whole diet.
The clip has since gone viral on her TikTok account @ kathrynelizabethx with over 160k views and 2,000 likes.
People were quick to share their experiences in the comments.
One person wrote: "My nausea is so bad for the first two days and I have absolutely no appetite whatsoever! I feel like I can't win."
Another commented: "Completely agree with all of this! I'm at the end of my 5th week and lost 18lbs. Feeling good, and both myself and friends have said they can see a difference."
"Do you still have to drink water even if you've got no side effects?" penned a third.
What are the other side effects of weight loss jabs?
Like any medication, weight loss jabs can have side effects.
Common side effects of injections such as Ozempic include:
Nausea: This is the most commonly reported side effect, especially when first starting the medication. It often decreases over time as your body adjusts.
Vomiting: Can occur, often in conjunction with nausea.
Diarrhea: Some people experience gastrointestinal upset.
Constipation: Some individuals may also experience constipation.
Stomach pain or discomfort: Some people may experience abdominal pain or discomfort.
Reduced appetite: This is often a desired effect for people using Ozempic for weight loss.
Indigestion: Can cause a feeling of bloating or discomfort after eating.
Serious side effects can also include:
Pancreatitis: In rare cases, Ozempic may increase the risk of inflammation of the pancreas, known as pancreatitis, which can cause severe stomach pain, nausea, and vomiting.
Kidney problems: There have been reports of kidney issues, including kidney failure, though this is uncommon.
Thyroid tumors: There's a potential increased risk of thyroid cancer, although this risk is based on animal studies. It is not confirmed in humans, but people with a history of thyroid cancer should avoid Ozempic.
Vision problems: Rapid changes in blood sugar levels may affect vision, and some people have reported blurry vision when taking Ozempic.
Hypoglycemia (low blood sugar): Especially if used with other medications like sulfonylureas or insulin.
Kathryn replied: "Yes! I found that the days I haven't drunk enough water I get the side effects the next day. It's a vicious cycle."
Meanwhile a fourth said: "Looking fabulous! Well done!"
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
41 minutes ago
- The Guardian
As an NHS GP, I can now prescribe weight-loss jabs – but a quick fix for obesity is not what we need
A medicine that takes away your appetite by making you feel full and a bit nauseous doesn't sound very attractive, but it is a price many people are ready to pay for the chance to lose weight. Although widely available privately, until this week only doctors in specialist clinics were allowed to prescribe tirzepatide (Mounjaro) to treat obesity on the NHS and it was almost impossible for GPs to get their patients into these clinics. People up and down England will no doubt rejoice at the news that their own doctor can now prescribe it. Any celebrations may be premature, as the criteria for prescription in the first phase of the rollout are so tightly drawn that few patients will qualify. You need a body mass index (BMI) of more than 40, which corresponds to a weight of 102kg (16st) for a woman of average height or 123kg (more than 19st) for a man. (The BMI criterion is slightly lower if you come from a high-risk group.) To be eligible, patients need to be not just at risk of complications from their obesity, but already suffering from them. They must have existing diagnoses of four out of five specific conditions: type 2 diabetes, high blood pressure, abnormal levels of fats in the blood (dyslipidaemia), obstructive sleep apnoea and damage to blood vessels. Individually, all of these conditions are fairly common, and they are more likely if you are obese. However, in our GP practice of 12,500 patients, we have identified only two who meet these criteria. Anticipating a rush of inquiries, we have asked our reception staff to tell patients that we will contact them if they qualify. In the second phase of the rollout, expected next summer, the BMI threshold will be lowered, although as the list of conditions will stay the same, it seems unlikely many more of my patients will qualify. I have some patients who are really stuck with very severe obesity, with a BMI of more than 50, who I think would benefit from this medication, yet I cannot prescribe it as they do not have the specified diagnoses. One of the reasons for the slow pace of the rollout mandated by NHS England is probably a fear of overwhelming GP services. Six hours of training is advised before we start prescribing, and patients should be seen monthly and monitored for adverse effects as the dose is increased, and then every six months. As the criteria relax, and the number of eligible patients expands, this will add up to a lot of extra appointments. Along with the injections, patients should also have 'wraparound care', which will provide diet and exercise advice. We are waiting to hear from our integrated care board about exactly how this will be provided to our patients, but the dietary advice is important. Many people who are obese are nevertheless malnourished as the food they eat is often high in fat and sugar and low in essential nutrients. If, in response to appetite suppression, they eat very much less of the same low-quality food, they may run into significant problems with lack of protein, vitamins and minerals. Dehydration may also be a problem as thirst is reduced as well as hunger. Rapid weight reduction causes loss of bone and muscle mass as well as fat, so exercise is needed to prevent frailty. Tirzepatide is not cheap: at the maximum dose, it costs £122 a patient a month, or £1,464 a year. This could be considered a bargain if you compare it with the cost of treating obesity-related conditions, and we should factor in the improvements in quality of life that achieving a healthy weight will bring. However, there are big questions to answer around how long people should use weight-loss drugs for, and what happens when they stop. Rebound weight gain is almost universal after a period of dieting but it appears to be even more rapid after taking drugs such as tirzepatide; one study has found that patients can expect to return to their original weight within under two years of stopping. This feels inevitable, as much of dieting is learning to change your response to your body's signals of hunger; if you've been taking a drug that abolishes those signals, then when you stop and your appetite returns, you are likely to respond exactly as you did in the past. At a population level, I worry that by concentrating on this technical, pharmaceutical fix to our obesity problem, we are heading down the wrong path. More than a quarter of the adult population in England is obese, and medicating them all in perpetuity surely cannot be the answer. If the government is serious about its much-heralded shift from treatment to prevention, we need bolder and more imaginative plans to tackle obesity. We need restrictions on the availability of calorie-dense, nutritionally poor, fast food. Taxing sugar and fat would be one way of altering the nation's diet, and we should also look at the quality of school meals. Beyond food regulation, we need to buy back school playing fields, offer opportunities to exercise for free, and encourage active transport by making pavements pleasant and cycle routes safe. The current obesity crisis arises from a complex mix of social and commercial determinants of health and these are not problems that can be fixed with a simple injection. Helen Salisbury is a GP in Oxford
Wales Online
2 hours ago
- Wales Online
Hundreds of reactions and multiple deaths linked to weight-loss jabs
Hundreds of reactions and multiple deaths linked to weight-loss jabs Health officials have immediately launched a new study to investigate the reported problems A woman injecting the weight loss drug semaglutide Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting health officials to launch a new study into side effects. Some cases of pancreatitis reported to be linked to GLP-1 medicines (glucagon-like peptide-1 receptor agonists) have been fatal. Data from the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), shows that since the drugs were licensed there have been hundreds of cases of acute and chronic pancreatitis among people taking GLP-1 medicines. This includes: 181 reported cases of acute and chronic pancreatitis linked to tirzepatide – the active ingredient for Mounjaro. Five people died. 116 reported reactions of this kind linked to liraglutide, one of which was fatal. 113 cases of acute and chronic pancreatitis linked to semaglutide – the active ingredient for Ozempic and Wegovy. One person died. 101 reported reactions of this kind linked to exenatide, three people died. 52 reported reactions of this sort linked to dulaglutide and 11 reported reactions lixisenatide. No fatalities were linked to either drug. These cases are not confirmed as being caused by the medicines, but the person who reported them suspected they may be. Nonetheless, Yellow Card Biobank project, launched by the MHRA and Genomics England, will see researchers examine whether cases of pancreatitis linked to GLP-1 drugs may be influenced by peoples genetic makeup. The MHRA is calling for people who are taking GLP-1 medicine who have been admitted to hospital due to acute pancreatitis to submit a report to its Yellow Card scheme. When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Article continues below Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs. Health officials have suggested that they can help to turn the tide on obesity, but have stressed they are not a silver bullet and do come with side effects. Most side effects linked to the jabs are gastrointestinal including nausea, constipation and diarrhoea. And the medical regulator recently warned that Mounjaro may make the oral contraceptive pill less effective in some patients. Dr Alison Cave, MHRA's chief safety officer, said: 'Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. 'Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions – enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup. To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. 'Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety.' Article continues below Professor Matt Brown, chief scientific officer of Genomics England, said: 'GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. We believe there is real potential to minimise these with many adverse reactions having a genetic cause. 'This next step in our partnership with the MHRA will generate data and evidence for safer and more effective treatment through more personalised approaches to prescription, supporting a shift towards an increasingly prevention-focused healthcare system.'
Daily Mirror
3 hours ago
- Daily Mirror
Ten people die after agonising reaction to weight loss jabs
MHRA says users of jabs such as Wegovy and Mounjaro reported inflamed pancreas - which can cause agonising abdominal pain - before their deaths as a major investigation has been launched A probe has been launched into why ten people died after reporting a severe side effect to weight loss injections. The Medicines and Healthcare products Regulatory Agency (MHRA) has launched an investigation after hundreds of users reported problems with their pancreas. The regulator's 'Yellow Card' scheme will now ask anyone who reports pancreatitis after taking the appetite-suppressing jabs to provide a DNA sample. It comes after Government ministers and some health leaders have called for the injections to be more widely available to tackle Britain's obesity epidemic and targeted at areas of high unemployment to help get people back to work. Professor Matt Brown, chief scientific officer of Genomics England, which will also run the study, said: "GLP-1 medicines like Ozempic and Wegovy have been making headlines, but like all medicines there can be a risk of serious side effects. We believe there is real potential to minimise these with many adverse reactions having a genetic cause.' Weight loss jabs slow digestion and reduce appetite by mimicking hormones which regulate hunger and feelings of fullness. They are designed to act like one of these hormones, known as glucagon-like peptide 1 (GLP-1). Last year it was reported that Susan McGowan was the first Brit believed to have died after taking weight loss injections. The 58-year-old took two Mounjaro injections before her death in September. Susan's death certificate listed multiple organ failure, septic shock and pancreatitis as the immediate cause. It was believed to be the first confirmed death linked to a GLP-1 injection but it is not known whether her case was reported to the Yellow Card scheme. Pancreatitis is inflammation of the organ located behind the stomach that aids in digestion and blood sugar regulation. It can cause sudden, severe abdominal pain, often radiating to the back. Other symptoms are nausea, vomiting, fever and a rapid heartbeat. The Yellow Card scheme is the way anyone can report to the MHRA if they have had an adverse reaction to a drug. The MHRA data shows: 181 reported cases of acute and chronic pancreatitis linked to Mounjaro. Five of these people died 113 cases of acute and chronic pancreatitis linked to semaglutide - branded as Ozempic for diabetes and Wegovy for obesity - and one person died 116 users of the weight loss jab Saxenda reported having pancreatitis and one died Exenatide, known by its brand names Byetta and Bydureon, was linked to 101 similar reactions after which three died These cases are not confirmed as being caused by the medicines but the person who reported them suspected they were. It comes after data released from the MHRA under Freedom of Information laws found there had been a total of 111 "suspected adverse drug reactions with a fatal outcome" up to May 2025. Responding to a freedom of information request from Chemist + Druggist, the MHRA added: "Underlying or previously undiagnosed illness unrelated to the medicine can also be factors in such reports." However the latest data release focuses on fatal cases where side effects affected the pancreas. Dr Alison Cave, MHRA's chief safety officer, said: "Evidence shows that almost a third of side effects to medicines could be prevented with the introduction of genetic testing, it is predicted that adverse drug reactions could cost the NHS more than £2.2 billion a year in hospital stays alone. Information from the Yellow Card Biobank will help us to better predict those most at risk of adverse reactions - enabling patients across the UK to receive the safest medicine for them, based on their genetic makeup.' When a Yellow Card report is received, the MHRA will contact patients to ask if they would be willing to take part in the study. Patients will be asked to submit more information and a saliva sample which will be assessed to explore whether some people are at a higher risk of acute pancreatitis when taking these medicines due to their genes. GLP-1 agonists can lower blood sugar levels in people living with type 2 diabetes and can also be prescribed to support some people with weight loss. Recent estimates suggest that about 1.5 million people in the UK are taking weight loss jabs, mostly via private prescriptions. Some have reported having to stop taking them due to side effects, particularly nausea. The new study is part of the UK Biobank project which is the biggest of its kind in the world and holds genetic data on half a million Brits. Dr Cave added: "To help us help you, we're asking anyone who has been hospitalised with acute pancreatitis while taking a GLP-1 medicine to report this to us via our Yellow Card scheme. Even if you don't meet the criteria for this phase of the Biobank study, information about your reaction to a medication is always extremely valuable in helping to improve patient safety." It comes after GPs started offering the jab Mounjaro this week with it being prescribed first to those most overweight. Before it was only prescribed to on the NHS to patients already accessing specialist weight management clinics. A spokesperson for Novo Nordisk, which manufactures Wegovy and Ozempic, said: 'Patient safety is of the utmost importance to Novo Nordisk. Like all medications, side effects can occur and vary from patient to patient. The known risks and benefits of GLP1 medicines are described in the Summary of Product Characteristics. 'We recommend that patients take these medications only for their approved indications and under the strict supervision of a healthcare professional, who can also advise on potential side effects. 'We continuously collect safety data on our marketed GLP-1 medicines and work closely with the authorities to ensure patient safety. The benefit-risk profile of our GLP-1 medicines remains positive, and we welcome any new research that will improve our understanding of treatments for people living with chronic diseases.' A spokesman for Eli Lilly, which makes Mounjaro, said: 'Patient safety is Lilly's top priority. We take reports regarding patient safety seriously and actively monitor, evaluate, and report safety information for all our medicines. Adverse events should be reported under the MHRA's Yellow Card scheme, but may be caused by other factors, including pre-existing conditions. 'The Mounjaro Patient Information Leaflet warns that inflamed pancreas - acute pancreatitis - is an uncommon side effect which may affect up to one in 100 people. It also advises patients to talk to their doctor or other healthcare professional before using Mounjaro if they have ever had pancreatitis. 'We encourage patients to consult their doctor or other healthcare professional regarding any side effects they may be experiencing and to ensure that they are getting genuine Lilly medicine.' NHS leaders warn jabs are not 'quick fix' Prescribing guidelines state that weight loss injections should be part of a comprehensive weight management plan including tailored diet and exercise advice. Side effects - particularly nausea and stomach cramps - can mean people stop taking the jabs. Some also find they can no longer afford the private prescriptions. The injections can see users lose around a fifth of their body weight but, crucially, this includes muscle as well as fat. Without drastic lifestyle changes research shows people pile fat back on a year after they stop taking the injections - but not the muscle. This makes it harder for them to lose weight again in future as they have less muscle to burn calories. Anyone considering the injections should consult their GP.
